Lymphoma of Mucosa-Associated Lymphoid Tissue
2
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by Rituximab
Related Conditions
Often studied with 6 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 2 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma
Research Network
Common Treatments
- Rituximab2
- Dexamethasone1
- 2cda1
- Lenalidomide1
Active Sponsors
- Abramson Cancer Center at Penn Medicine1
- Lipomed1
- Arbeitsgemeinschaft medikamentoese Tumortherapie1
- Roche1
Top Investigators
University of Pennsylvania
AKH Wien / Universitaetsklinik fuer Innere Medizin I
Related Conditions
- Lymphoma Small Lymphocytic1
- Follicular Lymphoma1
- Malt Lymphoma1
- Marginal Zone Bcell Lymphoma1
- Mantlecell Lymphoma1